J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.
Shubhchintan Randhawa,Byung Sik Cho,Byung Sik Cho,Dipanjan Ghosh,Mariela Sivina,Stefan Koehrer,Markus Müschen,Amnon Peled,Richard E. Davis,Marina Konopleva,Jan A. Burger +10 more
TL;DR: Findings corroborate that CXCR4 is an important target to overcome stroma‐mediated drug resistance in B‐ALL and indicate that anti‐leukaemia activity of CX CR4 antagonists is primarily due to CxCR4 inhibition, rather than agonistic activity.
Journal ArticleDOI
Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jennifer R. Brown,Peter Hillmen,Susan O'Brien,Jaqueline C. Barrientos,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Patrick Thornton,Federico Caligaris-Cappio,Julio Delgado,Marco Montillo,Sven DeVos,Carol Moreno,John M. Pagel,Jan A. Burger,Devon Chung,Jennifer H. Lin,Linda Gau,Betty Chang,Jesse McGreivy,Danelle F. James,John C. Byrd +27 more
TL;DR: Byrd et al. as discussed by the authors reported updated efficacy results for the phase 3 RESONATETM(PCYC-1112) study of ibrutinib (ibr) vs ofatumumab (ofa), relative to genetic features and prior treatment exposure, and provide updated adverse event (AE) data.
Journal ArticleDOI
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
TL;DR: Collectively, stroma-induced apoptosis resistance is mediated through signaling proteins that regulate transcriptional and translational expression and post-translational modification of Mcl-1 in CLL cells in context to bone marrow stromal microenvironment.
Journal ArticleDOI
Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Susan O'Brien,Nicole Lamanna,Thomas J. Kipps,Ian W. Flinn,Andrew D. Zelenetz,Jan A. Burger,Leanne Holes,Yoonjin Cho,Ronald L. Dubowy,Steven Coutre +9 more
TL;DR: The selectivePI3K-delta inhibitor Idelalisib (Zydelig®, IDELA), in combination with rituximab (R), has been previously reported to yield a 97% ORR in treatment naive patients (pts) ≥65 years with CLL or SLL, and this report is an update on that initial cohort of study pts.
Journal ArticleDOI
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
TL;DR: In the relapsed setting, these agents produce durable remissions, and might be preferable to re-treatment with chemoimmunotherapy for many patients, and underscore the advancement in the understanding of the biology of CLL.